Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report

As the last opportunity to assess treatment effect modification in a controlled setting prior to formal approval, clinical trials are a critical tool for understanding the safety and efficacy of new treatments in diverse populations. Recruitment of diverse participants in Alzheimer’s Disease (AD) cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Raman, Rema, Aisen, P., Carillo, M. C., Detke, M., Grill, J. D., Okonkwo, O. C., Rivera-Mindt, M., Sabbagh, M., Vellas, B., Weiner, M., Sperling, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
CTAD Task Force Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098373/
https://www.ncbi.nlm.nih.gov/pubmed/35841239
http://dx.doi.org/10.14283/jpad.2022.50

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098373/
https://www.ncbi.nlm.nih.gov/pubmed/35841239
http://dx.doi.org/10.14283/jpad.2022.50

Ejemplares similares